PISCATAWAY, N.J. — Camber Pharmaceuticals announced the addition of rufinamide oral suspension to its product line. Following the launch of Rufinamide Tablets in 2021, this new addition completes the Rufinamide product family.
Rufinamide oral suspension is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients 1 year of age and older, and in adults.
Rufinamide oral suspension 40 mg/mL is available in a 460 mL bottle with child-resistant closure along with two calibrated oral dosing syringes and an adapter.
To learn more about rufinamide oral suspension, please visit https://www.camberpharma.com/rufinamide-oral-susp
